Regencell Bioscience Holdings Limited (RGCB)
|Net Income (ttm)||-812,371|
Regencell Bioscience Holdings, which is developing formulations of traditional Chinese medicine for ADHD and ASD, filed on Monday with the SEC to raise up to $18 million in an initial public offering.
Regencell Bioscience has filed to go public with an IPO on the NASDAQ.
Regencell Bioscience is an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (\"TCM\") for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”). Our goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the best treatment of ADHD and ASD globally. We have three standardized TCM formulae candidates u... [Read more...]
Medicinal Chemicals & Botanical Products
|IPO Date |
|Stock Exchange |
|Ticker Symbol |